Sunesis Ups the Ante on Vosaroxin

Before you go, we thought you'd like these...
Before you go close icon

In the following video, Fool.com health care bureau chief Brenton Flynn discusses Sunesis Pharmaceuticals, one of the biggest movers in the health care industry on Tuesday. The stock soared following a press release that announced plans to add 225 patients to its existing phase 3 trial for Vosaroxin. The decision follows a review of trial data from the company's independent Data and Safety Monitoring Board, suggesting that initial readings on efficacy are positive. However, the huge positive move comes after an abrupt sell-off in shares during the final hour of Monday's trading, making the stock essentially flat for the past two trading days. 

Dealing with extreme volatility is just a way of life for investors in the world of clinical stage drug companies. It's okay to make very small speculative bets here and there, but when it comes to retiring well, there are some tips that every investor needs to know. In our free report titled "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you, as well as some winning wealth-building strategies. Click here to keep reading.

The article Sunesis Ups the Ante on Vosaroxin originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners